Athenex Inc
F:2MT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sungei Bagan Rubber Company Malaya Bhd
KLSE:SBAGAN
|
MY |
|
P
|
Pantoro Ltd
ASX:PNR
|
AU |
|
United Spirits Ltd
NSE:MCDOWELL-N
|
IN |
|
L
|
Lay Hong Bhd
KLSE:LAYHONG
|
MY |
|
G
|
Green Technology Metals Ltd
ASX:GT1
|
AU |
|
Ateam Inc
TSE:3662
|
JP |
Athenex Inc
Long-Term Debt
Athenex Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Athenex Inc
F:2MT
|
Long-Term Debt
$86.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
181%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$58.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$22.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$50B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$106.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
22%
|
|
Athenex Inc
Glance View
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
See Also
What is Athenex Inc's Long-Term Debt?
Long-Term Debt
86.8m
USD
Based on the financial report for Dec 31, 2022, Athenex Inc's Long-Term Debt amounts to 86.8m USD.
What is Athenex Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
181%
Over the last year, the Long-Term Debt growth was -16%. The average annual Long-Term Debt growth rates for Athenex Inc have been 18% over the past three years , 181% over the past five years .
